WASHINGTON, July 2, 2018 /PRNewswire/ --
The world-leading medical solutions company, Molnlycke, has acquired German wound care products company, SastoMed GmbH. The deal adds new, award-winning products to Molnlycke's offer – enabling it to further help healthcare professionals and patients by accelerating the wound healing process and treating chronic wounds.
As of today, SastoMed GmbH joins the Molnlycke family, bringing two innovative and complementary products to Molnlycke's wound care portfolio:
- Granulox®: a haemoglobin-based topical oxygen therapy spray that is sprayed on wounds for faster wound healing.
- Granudacyn®: ahypochlorous wound irrigation solution for cleaning, moistening and rinsing of acute, chronic and contaminated wounds, and first and second degree burns.
The addition of the new products will enable Molnlycke to lead the way in both active and passive wound healing.
"Today, chronic wounds, such as foot ulcers, have a higher mortality rate than both breast cancer and prostate cancer and the real burden of ulcers is not yet fully known or understood. Molnlycke will now be able to offer healthcare professionals – and patients – solutions to support both active and passive healing. We can therefore offer a holistic approach to wound treatment through our portfolio," says Molnlycke CEO, Richard Twomey.
With the acquisition of SastoMed GmbH, Molnlycke adds another award-winning product to its wound care offer. Earlier this year, Granulox won the 2018 Innovation Award at EWMA (European Wound Management Association) Congress in Krakow thanks to its ability to advance the healing process. Studies report that Granulox can reduce total costs of initial Diabetic foot ulcers treatment by around 60% a year.
Complementary innovation and sales capabilities
Over the past few years, Molnlycke has invested in organic R&D to meet customer needs and bring innovative products to the market. The acquisition complements this investment with new technology and capabilities, further accelerating Molnlycke's potential for product innovation.
Furthermore, both Granulox and Granudacyn fit into Molnlycke's strategy to be a category leader within the wound care space.
Share the desire to help patients
While Granulox is currently available in more than 24 countries, SastoMed's main customer base is in Germany, South East Asia and Central and Latin America. Molnlycke will expand the geographical reach of Granulox and Granudacyn through its worldwide distribution network and sales organisation. With customers and a salesforce in South East Asia and Central and Latin America, the acquisition of SastoMed also enables Molnlycke to expand its presence in key growth markets.
The founder of SastoMed, Michael Sander, comments: "We share Molnlycke's desire to advance healthcare around the world. Too often, patients experience slow wound healing since no appropriate therapy is available to overcome the lack of oxygen in the wound tissue. Now we feel it´s the right time to pass the baton to the leading company in advanced wound care, in order to make our unique products available to as many patients as possible.'"
- SastoMed GmbH wins Wound care Innovation Award, https://www.alirahealth.com/news/sastomed-gmbh-wins-wound-care-innovation-award/
- Oxygen wound therapy: The clinical and cost impact of using topical haemoglobin spray (Granulox®). London: Wounds UK, 2017. Available to download from: www.wounds-uk.com
The Molnlycke Health Care, Biogel, HIBICLENS, Mepilex, Safetac and Indicator trademarks, names and logo types are registered globally to one or more of the Molnlycke Health Care Group of Companies. Z- Flo is a trademark in the United States and other countries of EdiZONE, LLC of Alpine, Utah, USA. Distributed by Mölnlycke Health Care US, LLC, Norcross, Georgia 30092. © 2017 Mölnlycke Health Care AB. All rights reserved. 1-800-882- 4582.
For more information, please contact:
Global Communications Manager
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release - Mölnlycke acquires SastoMed GmbH
Granudacyn and Granulox